Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

The tennis star has sparked an online debate about whether or not using GLP-1s for weight loss is taking the easy way out.

Health insurance will grow more expensive in many corners of the market in 2026, and some coverage may shrink.

Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a ...

Celebrities have access to doctors that most others don’t,” says Jameela Jamil, who flagged the risks of GLP-1s like those ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” second-quarter 2025 ...

About 12% of all U.S. adults have already tried using GLP-1 agonist drugs to control their weight, according to a survey ...

Pricey prescriptions and nagging medical costs are swamping some insurers and employers now. Patients may start paying for it next year.

Actor Jameela Jamil is calling out the press for inaccurately reporting on what she said about Serena Williams and GLP-1s. Here's what she explained.

Eli Lilly and Novo Nordisk already make popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site will, too.

It’s a grand slam partnership for telehealth provider Ro. World renowned tennis star Serena Willams is partnering with the ...